Molecular Partners (NASDAQ:MOLN) Trading Up 2.7% – Should You Buy?

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN)’s stock price rose 2.7% during mid-day trading on Thursday . The company traded as high as $4.28 and last traded at $4.24. Approximately 1,246 shares were traded during trading, a decline of 88% from the average daily volume of 10,531 shares. The stock had previously closed at $4.13.

Analyst Ratings Changes

A number of brokerages recently issued reports on MOLN. JPMorgan Chase & Co. dropped their price objective on Molecular Partners from $4.50 to $4.00 and set a “neutral” rating on the stock in a report on Wednesday, September 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Molecular Partners in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Molecular Partners presently has an average rating of “Hold” and a consensus target price of $8.00.

Molecular Partners Trading Up 2.7%

The stock has a market cap of $171.21 million, a PE ratio of -2.21 and a beta of 1.09. The firm has a fifty day simple moving average of $3.80 and a two-hundred day simple moving average of $3.79.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings data on Thursday, October 30th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.05. Equities analysts forecast that Molecular Partners AG Sponsored ADR will post -1.93 earnings per share for the current year.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.